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1607-551X/Copyright ª 2014, KaohsiuAbstract The aim of the present study was to evaluate the efficacy of cyclosporine A (CsA)
combined with medium/low dose prednisone in the treatment of progressive immunoglobulin A
nephropathy (IgAN). Ninety-six patients who satisfied the inclusion criteria were enrolled in a
prospective controlled clinical study. They were assigned into two groups and initially given
either 0.6e0.8 mg/kg/day prednisone (maximum 40 mg/day) plus 3 mg/kg/day CsA (CsA
group), or 1 mg/kg/day prednisone (maximum 60 mg/day) alone (steroid group). During ther-
apy, the dose of prednisone was reduced in both groups and the dose of CsA was gradually
tailed off over the first 3 months and maintained at 2 mg/kg/day in the CsA group. Urinary pro-
tein excretion, serum biochemical indexes, clinical efficacy and side effects of CsA were as-
sayed. A significant decline in mean 24-hour urinary protein excretion (p < 0.05) was
observed 1 month after treatment in patients in the CsA group, which was observed 2 months
after treatment in the steroid group. The decline in mean 24-hour urinary protein excretion in
the CsA group was more significant than in the steroid group. Serum albumin level increased
significantly in the CsA group 2 months after therapy (p < 0.05). Moreover, at the end of
the course, a higher remission rate was observed in patients with Lee’s Grade III IgAN after
combined treatment with prednisone and CsA (p < 0.05). No significant difference in clinical
efficacy was observed in patients with Lee’s Grade IV and Grade V IgAN between the two
groups (p > 0.05). CsA at a dose of 2e3 mg/kg/day in combination with medium/low dose
prednisone was effective in inducing remission of IgAN, especially for patients with Lee’seclare no conflicts of interest.
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Cyclosporine A with prednisone in IgA nephropathy 391Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with pro-
gressive IgAN.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Immunoglobulin A nephropathy (IgAN) is recognized to be
the most common type of primary glomerulonephritis
worldwide [1,2]. Some IgAN patients have stable renal
function over several decades, whereas others develop
hypertension, nephrotic syndrome, and chronic renal
failure [3]. A variety of mechanisms have been demon-
strated to be involved in the pathogenesis of IgAN, of
which, immune abnormalities including activation of T
lymphocytes play important roles, and secondary inflam-
mation caused by abnormal growth factors and cytokines
participate mainly in mesangial proliferation and sclerosis
[4]. Therefore, early diagnosis and intervention are
important for IgAN treatment. Recent studies suggest that
urine protein > 1.0 g/24 hour is an independent risk factor
for IgAN progression [4]. Thus, actively reducing urinary
protein and delaying IgAN progression are currently the
focus of treatment. Active treatment using corticoste-
roids, immunosuppressants, angiotensin-converting
enzyme inhibitors and/or angiotensin-receptor blockers
(ARBs) is advocated for patients with initial proteinuria
(>1 g/day) accompanied with hypertension, and patients
with progressive IgAN as indicated by diagnostically
confirmed renal dysfunction, glomerular sclerosis, cres-
cent formation, interstitial fibrosis, and vascular sclerosis
[4]. Studies have reported that prednisone can reduce
urinary protein, protect renal function, and delay the
progress of IgAN [5]. However, many patients with IgAN are
not sensitive to corticosteroid therapy as clinically man-
ifested as urinary protein sustainably greater than 1 g/24
hour or decreased less than 25% after 12 weeks of pred-
nisone treatment. In addition, these patients generally
have Lee’s Grade III or higher IgAN in renal biopsy.
Therefore, they are generally treated with immunosup-
pressants besides prednisone therapy.
Cyclosporine A (CsA), a potent, highly selective immu-
nosuppressant, has been widely used to treat patients with
organ transplantation and autoimmune diseases. Compared
with other immunosuppressive agents, CsA selectively acts
on T lymphocytes without affecting bone marrow myeloid
and erythroid cells. Many clinical studies have indicated
that CsA has good clinical efficacy in the treatment of
minimal change nephrosis, focal segmental glomerulo-
sclerosis, as well as idiopathic membranous nephropathy-
induced nephrotic syndrome. However, its application in
the treatment of progressive IgAN is rarely reported.
Therefore, we selected inpatients who were diagnosed by
renal biopsy to have Lee’s Grade III or higher IgAN and used
prospective, controlled clinical studies to explore the
clinical efficacy and safety of joint treatment with CsA and
medium/low-dose prednisone in patients with progressive
IgAN.Methods
Patients
From June 2005 to May 2012, a total of 96 inpatients who
met the following criteria were enrolled in the present
study: (1) renal pathology proved to be IgAN by renal bi-
opsy; (2) Lee’s Grade IIIeV; (3) serum creatinine (Scr)
<150 mmol/L or estimated glomerular filtration rate (eGFR)
> 60 mL/minute; and (4) urinary protein excretion rate
1.0e3.5 g/24 hour. Patients were excluded or exited from
the trial regardless of efficacy if: (1) they had an infection,
liver and systemic disease, diabetes mellitus, or neo-
plasms; (2) they were pregnancy or during lactation; or (3)
they had allergic purpura, ankylosing spondylitis, systemic
lupus erythematosus, Sjogren’s syndrome, psoriasis, or
other secondary IgAN. End points of the study were: (1) end
of follow-up; (2) Scr concentration doubled, or eGFR
reduced by >50%; and (3) serious adverse events. The
treatment protocol was approved by the Institutional Re-
view Board of Taian Central Hospital and was consistent
with all of the patients. Informed consent was obtained
from each participant. Ethical approval for this study was
obtained from the Medical Ethical Committee of Taian
Central Hospital, Taian. China.Experimental group
Patients including 24 males and 24 females with a mean age
of 35.4  7.3 were assigned to CsA group. 48 cases in ste-
roid group including 28 males and 20 females with the
average age of (34.5  8) years old.
Patients in the CsA groupwere given oral CsA (Oral Cyspin;
Hangzhou Zhongmei-Huadong Pharmacentical Co. Ltd.,
Hangzhou, China) at 3 mg/kg/day in the first 3 months, then
maintenance with 2 mg/kg/day for 9 months for patients
who had clinical improvement. CsA administration was
stopped promptly if patients had suspected CsA-associated
nephrotoxicity or when no clinical improvement occurred
after 4e6 months of treatment. The dose of CsA was
adjusted to ensure the concentration was maintained at
100e150 ng/ml. Prednisone (Shandong Xinhua Pharmaceu-
tical Co. Ltd., Zibo, China, 0.6e0.8 mg/kg/day maximum,
40 mg/day) was given to patients in the CsA group every
morning for 6e8 weeks. The dose was then gradually
reduced by 5 mg every 2 weeks to 10 mg/day during.
Patients in the steroid group were given prednisone
(1.0 mg/kg/day maximum, 60 mg/day) every morning for
8e12 weeks. The dose was then gradually reduced by 5 mg
every 2 weeks to 20 mg/day, and then by 2.5 mg every 2
weeks to 10 mg/day. This was the maintenance dose for 1
year.
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groups.All patientsweregivenARB(Valsartan80e160mg/day;
Beijing Novartis Pharma Ltd, Beijing, China) and hypertension
was controlled with ARB and/or nifedipine and/or diuretics.
Measurement of laboratory indexes
All patients were followed-up twice in the 1st month, once
in the 2nd month, and thereafter once every 4e6 months.
Serum albumin, Scr, blood urea nitrogen, cholesterol, tri-
glyceride, uric acid, fasting blood glucose, eGFR, and 24-
hour urinary protein excretion rate were examined.
Remission rate and drug side effects were closely observed
and confirmed with repeat examination of 24-hour urinary
protein excretion rate and serum albumin.
Efficacy was defined as complete remission (CR) and
partial remission (PR). CR was defined as proteinuria
<0.5 g/24 hours, serum albumin > 35 g/L, and normal Scr.
PR was defined as proteinuria reduced by >25% but still
higher than 0.5 g/24 hours, and stable Scr. Invalid was
defined as proteinuria reduced <25% or worsening of renal
function [6].
CsA level (C0) were monitored by high performance liquid
chromatography (HPLC) (CsA standard: The Control of Phar-
maceutical and Biological Products of China; Cyclosporine D
(CsD) the internal standard: North China Pharmaceutical
Research Institute) weekly for 1 month and thereafter
monitored monthly. Methanol and acetonitrile (Tianjin Siyou
Chemical Reagent Factory, Tianjin, China, analytic reagent);
Ether (Tianjin Tianda Chemical Experiment Factory, Tianjin,
China); N-hexane (Tianjin Chemical Reagent Factory, Tian-
jin, China, analytic reagent). HPLC was developed using
acetonitrile-methanol-water (60:20:20 by volume) as mobile
phase, Polaris C18 column (250 mm  416 mm, 5 mm) and
214 nm wavelength detection. The flow rate was 0.5 ml/
minute and the column temperature was 70C. One milli-
meter of CsD (dissolved in methanol, concentration ofTable 1 Baseline demographic, clinical and laboratory charact
Steroid group (
Male/female 28/20
Age (y) 34.5  8.0
SBP (mmHg) 131.3  17
DBP (mmHg) 80.2  11.
MAP (mmHg) 95.5  10.
Patients with BP > 140/90 mmHg [n (%)] 10 (20.8)
Serum albumin (g/L) 33.93  7.
Proteinuria (g/d) 2.01  0.8
Serum creatinine (mmol/d) 87.3  22.
Lee’s Grade II 36
III 8
IV 4
Uric acid (mg/dL) 5.3  1.7
Cholesterol (mmol/L) 6.77  2.9
Triglyceride (mmol/L) 2.74  1.5
FBG (mmol/L) 5.1  0.7
eGFR (mL/min) 76.7  23.
BPZ blood pressure; CsAZ cyclosporine A; DBPZ diastolic blood pre
blood glucose; MAP Z mean arterial pressure; SBP Z systolic blood p500 ng/ml) was added to 1.5 ml blood samples. Then 1.5 ml
0.1 mol/ml NaOH and 5 ml ether were added to the mixture.
The mixture was stirred and extracted for 3 minutes, and
centrifuged at 3000 r/minute for 5 minutes. Then the su-
pernatantwas put in a 40Cwater bath and dried by nitrogen.
The residue was dissolved by 0.3 ml n-hexane. After that,
80 ml mobile phase was added, stirred and extracted for 1
minute, centrifuged at 3000 r/minute for 5 minutes, then
20 ml lower mobile phase was taken as the sample.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
version 12.0 (SPSS Inc., Chicago, IL, USA). Data were rep-
resented as mean  standard deviation. The data were
analyzed with repeated measures one-way analysis of
variance and application of comparison for paired data
analysis and for two-group variance analysis. Cumulative
proportions of patients with CR and/or PR in the two groups
were compared using the c2 test. Statistical significance
was set at the level of p < 0.05.
Results
Patient characteristics
Patients in the two groups had similar baseline de-
mographic, clinical, and laboratory characteristics
(Table 1). Their baseline sex and age distributions were
similar. Their systolic, diastolic, and mean blood pressure
showed no significant differences. The number of patients
with blood pressure higher than 140/90 mmHg at baseline
was also similar in the two groups: 10 (20.8%) in the steroid
group and 12 (25%) in the CsA group (p > 0.05). The mean
proteinuria values at baseline were 2.01  0.8 g/day
(range: 1.03e3.47 g/day) in the steroid group anderistics of patients.
n Z 48) CsA group (n Z 48) T (or Z) value p
24/24 x2 Z 0.671 0.413
35.4  7.3 0.576 0.566
134.7  14 1.070 0.288
5 83.2  10.7 1.323 0.189
2 96.8  9.7 0.640 0.524
12 (25)
6 33.96  6.5 0.021 0.984
2.07  0.9 0.345 0.730
05 89.9  19.87 0.607 0.545
32 Z Z 0.918 0.359
10
6
5.4  1.2 0.333 0.740
1 6.56  3.29 0.421 0.712
2 2.63  1.0 0.318 0.674
4.9  0.7 0.299 0.712
8 75.1  24 0.594 0.213
ssure; eGFRZ estimated glomerular filtration rate; FBGZ fasting
ressure.
Cyclosporine A with prednisone in IgA nephropathy 3932.07  0.9 g/day (range: 1.11e3.36 g/day) in the CsA group
(p > 0.05). Lee’s classification at the time of biopsy was III,
IV, and V in 36 patients, eight patients, and four patients,
respectively, in the steroid group and in 32 patients, 10
patients, and six patients, respectively, in the CsA group.
Renal function, estimated by Scr and eGFR, was similar in
the two groups. Information in Table 1 also suggested no
significant differences in serum albumin, uric acid,
cholesterol, triglyceride, and fasting blood glucose be-
tween the two groups.
Primary outcomes
Table 2 lists the clinical findings in the patients in the two
groups. There was a marked difference in urinary protein
excretion between different times and groups by repeated
measure with analysis of variance (times: F Z 112.435,
p < 0.0001; Groups: F Z 37.87, p < 0.0001), and in serum
albumin (times: FZ 42.022, p < 0.0001; Groups: FZ 5.57,
p Z 0.02). However, as shown in Table 2, Scr, serum uric
acid, mean arterial pressure, serum cholesterol, serum
triglyceride, fasting blood glucose, and eGFR did not
change significantly from baseline to the end of the study in
both groups. For patients in the CsA group, urinary protein
excretion decreased significantly from 2.07  0.9 g/day to
1.22  0.5 g/day after 1 month of treatment, and pro-
teinuria was reduced to 0.53  0.4 g/day (p < 0.01) after 12
months of follow-up. Similar outcomes were also observed
in patients in the steroid group. In addition, proteinuria
differed significantly between the two groups after 2Table 2 Comparison in clinical findings following treatment of
Group Time Proteinuria (g/d) Serum albumin (g/L) Se
Steroid 0.5M 1.96  0.6 33.90  6.5
1M 1.85  0.3 34.01  7.0
2M 1.52  0.4* 34.11  6.5
6M 1.23  0.5* 34.12  5.9
12M 1.01  0.6* 35.69  7.1
Cs A 0.5M 1.97  0.9 34.01  7.2
1M 1.22  0.5* 34.65  5.2
2M 0.87  0.6**, *** 38.49  5.4*, ***
6M 0.72  0.3**, *** 39.72  5.9*, ***
12M 0.53  0.4** 39.51  6.4*,***
Group Time Cholesterol (mmol/L) Triglyceride (mmol/L)
Steroid 0.5M 6.76  1.98 2.75  1.61
1M 6.73  1.82 2.77  1.39
2M 6.75  1.77 2.76  1.69
6M 6.72  1.80 2.76  1.46
12M 6.69  1.79 2.75  1.37
CsA 0.5M 6.62  2.97 2.69  1.14
1M 6.71  1.82 2.69  1.31
2M 6.71  1.73 2.67  1.49
6M 6.72  1.91 2.65  1.35
12M 6.71  1.76 2.65  1.41
*p < 0.05.
**p < 0.01 compared to the indexes prior to treatment in the same g
***p < 0.05 simultaneous comparison of indexes between two groups.
a Statistical analysis used one-way analysis of variance with t test.months and 6 months of therapy (p < 0.05), but not after 12
months of therapy. Serum albumin concentration increased
significantly after 2 months of treatment with CsA com-
bined with prednisone. Compared with the steroid group,
serum albumin increased significantly after 2e12 months of
combined therapy, and these changes were more significant
after 12 months of therapy. Although serum albumin level
also increased in patients treated with prednisone alone,
this increase did not reach statistical significance. The time
of action time for CsA was 21.3  6.7 days. Serum CsA
concentration was 132.5  55.1 ng/mL in patients who
reached complete remission and had an average CsA dose
of 2.64  0.57 mg/kg/day. Despite the satisfactory changes
in serum albumin concentration and urinary protein
excretion, we noticed no improvement of renal function or
alteration in renal creatinine concentration during com-
bined treatment with CsA and steroid.
Table 3 shows the clinical efficacy of the two treat-
ments. Complete remission occurred in 12.5%, 37.5%,
41.7%, and 52.1% patients after 1 month, 2 months, 6
months, and 12 months of combined treatment with CsA
and steroid, respectively. Although the efficacy of the two
treatments did not differ significantly after 6 months, it
differed significantly after 12 months. In addition, the
complete remission rate of patients in the CsA group was
significantly higher than that of patients in the steroid
group after 2 months of treatment (p < 0.05 or p < 0.01).
Table 4 shows the clinical efficacy of the two treatments
for IgAN patients with different Lee’s Grade. Patients with
Lee’s Grade III in the CsA group had a CR rate of 56.25% andtwo groups.a
rum creatinine (mmol/L) Uric acid (mg/dL) MAP (mmHg)
87.3  21.5 5.3  1.2 95.3  10.3
87.0  22.3 5.3  1.6 95.1  11.2
86.9  21.8 5.2  1.1 96.3  10.6
87.1  20.3 5.3  1.2 96.7  10.4
86.3  19.8 5.3  1.1 96.8  10.9
89.9  18.5 5.4  1.1 96.8  9.7
87.2  17.8 5.4  1.5 97.2  9.3
87.6  15.3 5.4  1.1 97.2  9.1
88.4  18.4 5.3  1.8 96.7  10.2
88.7  16.6 5.3  1.6 96.2  11.5
FBG (mmol/L) eGFR (ml/min) CsA concentration (C0)
5.1  0.5 76.4  21.4 e
5.2  0.8 78.9  26.2 e
5.0  0.6 78.4  24.9 e
4.9  0.5 77.5  30.1 e
4.7  0.7 78.6  27.8 e
4.9  0.7 75.6  27.3 102.7  18.4
4.8  0.8 74.8  23.6 108.6  14.9
4.5  0.5 75.1  20.9 111.4  13.7
4.3  0.7 76.4  21.7 106.7  20.1
4.7  0.5 77.3  25.4 107.3  15.2
roup.
n Z 48 for CsA group and n Z 48 for steroid group.
Table 3 The comparison of efficacy between two groups.a
Group n Time CR (%) PR (%) CR + PR (%)
Steroid 48 0.5 m 0 (0) 14 (29.2) 14 (29.2)
1 m 2 (4.2) 28 (58.3) 30 (62.5)
2 m 6 (12.5) 28 (58.3) 34 (70.8)
6 m 10 (20.8) 26 (54.2) 36 (75)
12 m 10 (20.8) 26 (54.2) 36 (75)
CsA 48 0.5 m 0 (0) 18 (37.5) 18 (37.5)
1 m 6 (12.5) 28 (58.3) 34 (70.8)
2 m 18 (37.5)** 22 (45.8) 40 (83.3)
6 m 20 (41.7)* 22 (45.8) 42 (87.5)
12 m 25 (52.1)** 19 (39.6) 44 (91.7)*
*p < 0.05.
**p < 0.01.
CR Z complete remission; CsA Z cyclosporine A; PR Z partial
remission.
a Statistical analysis used c2 test. Simultaneous comparison
between two groups.
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those of patients with Lee’s Grade III in the steroid group
(p < 0.05). The remission rates of patients with Lee’s Grade
IV and V IgAN were similar between the two groups
(p > 0.05). In addition, the remission rate of patients with
Lee’s Grade III IgAN in the CsA group was significantly higher
than that of patients with Lee’s Grades IV and V in the same
group (p < 0.05).
Several complications were observed in patients in the
CsA group. (1) Hypertension was found in four patients, who
were treated with antihypertensive therapy. (2) Liver
damage was found in three patients, who were successfully
managed by adjusting blood CsA concentration. (3) Over-
growth of body hair and gingiva were observed in nine pa-
tients and five patients, respectively. These symptoms
disappeared after tapering off the CsA dose. No infection,
leukopenia, renal impairment, hair loss, or other adverse
reactions were found. In the steroid group, six patients had
infection, five patients had hypertension, and eight pa-
tients had abnormal blood glucose. They all recovered after
appropriate therapies. All patients in the steroid groupTable 4 Comparison of clinical effect of different classi-
fication of CsA on IgAN.a
Group n Lee’s
Grade
CR (%) PR (%) CR þ PR
CsA 48 Ⅲ (32) 19 (59.38)*,** 13 (40.63) 32 (100)*
Ⅳ (10) 5 (50.0) 4 (40.0) 9 (90)
V (6) 1 (16.67) 2 (33.33) 3 (50)
Steroid 48 Ⅲ (36) 8 (22.22) 23 (63.89) 31 (86.11)
Ⅳ (8) 2 (25.0) 2 (25) 4 (50)
V (4) 0 (0) 1 (25) 1 (25)
*p < 0.05, comparison in different classification in the same
group.
**p < 0.05, comparison between two groups.
CR Z complete remission; CsA Z cyclosporine A; IgAN Z IgA
nephropathy; PR Z partial remission.
a Statistical analysis used c2 test.completed the trial. Two patients were lost to follow-up
after 3 months and 4 months treatment, respectively, and
two participants stopped using CsA after 6 months of
follow-up due to no clinical improvement.Discussion
Recent data have indicated that IgAN is a widespread type
of glomerulonephritis with relatively poor renal outcome.
Up to 40% of IgAN patients reach end-stage renal disease
within 20 years [1,2]. Several studies have proved that
steroids, angiotensin-converting enzyme inhibitors, fish oil,
cytotoxics, immunosuppressants, tonsillectomy, and
vitamin E are beneficial to IgAN patients [7e12]. However,
consensus about therapy is still lacking. CsA has no doubt
become the first-line therapy in organ transplantation since
the late 1970s. Its efficacy has led to its use in a variety of
immune-mediated glomerular diseases such as minimal
change disease, focal segmental glomerulosclerosis, mem-
branous nephropathy, membranoproliferative glomerulo-
nephritis, and lupus nephritis.
Shin et al. [13] used CsA to treat patients with severe
HenocheScho¨nlein nephritis with nephrotic syndrome for
an average of 5.5 years. They found declined urinary pro-
tein/24 hours, increased serum albumin, and significantly
decreased activity index at the second renal biopsies in all
patients after CsA therapy, but no decline in chronicity
index and tubulointerstitial scores, suggesting that CsA may
be beneficial to a subset of HenocheScho¨nlein nephritis
patients with nephrotic syndrome. Tao et al. [14] found
that low-dose CsA treatment of adult patients with
nephrotic syndrome complicated with idiopathic membra-
nous nephropathy for at least 6 months was safe and
effective, and all patients maintained CR without relapse.
However, the efficacy of CsA in IgAN patients remains
poorly studied. Shin et al. [15] treated 14 children with CsA
and steroids, and found the mean duration of CsA therapy
was 10.9  1.9 months. They believe that CsA may be
effective in reducing proteinuria and regressing renal pa-
thology in a subset of children with IgAN. Rasic et al. [16]
have demonstrated that a high percentage of adult pa-
tients with primary nephrotic syndrome associated with
IgAN achieve remission after CsA treatment. However, due
to limited experience, CsA treatment of IgAN was not
approved in the Last Summary of Therapeutic Options
published by Galla [17]. Lai et al. [18] published a small
study in 1987 in which CsA administered for 3 months
significantly reduced proteinuria, and this effect persisted
in some of the patients during a subsequent 12 weeks of
observation. The decrease in proteinuria was accompanied
by a reduction in glomerular filtration, which nevertheless
was not sufficient to explain the decrease in proteinuria.
The mechanisms of action of CsA are unclear, but may
involve the following: (1) immunomodulation by T-cell-
mediated cytokines, resulting in restoration of glomerular
basement membrane charge selectivity [19,20]; (2) inhibi-
tion of vascular permeability factors [21]; and (3) nonspe-
cific alteration of renal hemodynamics, reducing
proteinuria through functional renal insufficiency.
Our study showed that CsA treatment was effective in
reducing proteinuria and elevating serum albumin. The
Cyclosporine A with prednisone in IgA nephropathy 395combination of CsA and medium/low-dose prednisone was
more effective in reducing proteinuria and elevating plasma
albumin compared with the steroid group, suggesting a syn-
ergistic effect between CsA and prednisone. Although no
significant improvement of renal functionwas observed after
treatment, we did observe a trend towards improvement of
renal function. The outcome could have been due to the
short duration of the trial. In addition, no significant differ-
ences in CR rate and effective rate were observed 15 days
after treatment, but CR rate at 2 months and 6 months and
the effective rate at 12 months in the CsA group were higher
than those in the steroid group (p< 0.05 or p< 0.01). Despite
the effective rate after 6 months therapy not differing
significantly between the two groups, the CR rate in the CsA
group was higher than that in the steroid group. Thus, we
conclude that the combined treatment of CsA and medium/
low dose of prednisone is superior to prednisone pulse ther-
apy alone in IgAN. We also found that a higher remission rate
could be achieved in patients with Lee’s Grade III IgAN after
combined treatment with prednisone and CsA, indicating
that these patients could benefit more from CsA. No signifi-
cant difference in clinical efficacy was observed in classifi-
cation Lee’sⅣ andⅤpatients between the two groups. In our
opinion, the results may be relevant for small samples, short
time of observation, and in patients with serious histological
changes.
We also found no difference in cholesterol, triglyceride,
and blood sugar after treatment with CsA. Although there
were complications in some patients during therapy, they
all recovered by appropriate therapy. Our study indicated
that short-term combination of CsA and prednisone in pa-
tients with IgAN is safe.
Many studies have demonstrated the clinical effect of
CsA in kidney disease. However, its toxicity, especially its
nephrotoxicity, has limited its application. The current
study showed that CsA therapy was effective in regressing
renal histological changes in a subset of patients with IgAN
(w50%). Although there were no serious complications of
CsA therapy during the study, it is important to use the
lowest effective dosage of CsA and monitor the CsA level
closely. In addition, this study had several limitations such
as small sample size, not being a randomized double-blind
clinical trial, lack of repeat biopsy, and relatively short
length of treatment and follow-up.
In summary, our study suggests that CsA combined with
steroid is effective in reducing proteinuria and elevating
serum albumin in patients with progressive IgAN. The pa-
tients with Lee’s Grade III IgAN would benefit more from
combination of CsA and prednisone than those with Lee’s
Grade IV and V IgAN. The efficacy in our study was limited
to only 1 year of treatment and short-term follow-up, which
is not the final goal of patient management. More evidence
is needed to conclude that the combination of CsA and
prednisone may have better long-term effects (compared
with 1 year’s treatment). Further studies are required to
continue to clarify whether combined therapy is effective
in the advanced stage of IgAN and to confirm whether it
actually improves renal outcome over the long term.References
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